文献速递其他结缔组织病

早期弥漫性系统性硬化症临床试验设计的最佳病程界定

Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究基于匹兹堡大学硬皮病前瞻性队列(1980–2015年)的早期弥漫性SSc患者,比较了以首次SSc表现或首次非雷诺表现为起病定义、以及不同病程作为入组标准的影响。结果显示两种起病定义无显著差异,而病程<18个月入组时>70%患者随访6个月皮肤病变轨迹恶化;更长病程则多数患者mRSS轨迹改善(均值回归),可能解释既往试验阴性结果,故推荐入组病程<18个月。

要点

  • 首次SSc表现与首次非雷诺表现定义起病无实质差异。
  • 病程<18个月入组时>70%患者6个月内皮肤病变轨迹恶化。
  • 更长病程入组时多数患者mRSS轨迹改善(均值回归),或致试验阴性。

核心结论

  • 无论采用首次SSc表现还是首次非雷诺表现定义起病,入组时病程<18个月更优。
  • 更长病程标准更常导致mRSS均值回归,可能促成阴性试验结果。

研究设计与样本

  • 研究使用匹兹堡大学硬皮病前瞻性观察队列,纳入1980–2015年间首次评估的早期弥漫性SSc患者。
  • 患者距首次SSc表现<3年(n=481)或距首次非雷诺表现<3年(n=514),且至少有3次mRSS评分。
  • 采用描述性、生存和基于组的轨迹分析比较不同起病定义和病程入组标准。

主要发现

  • 以首次SSc表现与首次非雷诺表现定义起病相比,无显著差异。
  • 病程<18个月的患者中>70%在6个月随访内皮肤病变轨迹恶化。
  • 更长病程的患者多数在6个月内mRSS轨迹改善(均值回归)。

关键数值与推荐

  • 推荐临床试验入组采用病程<18个月作为纳入标准。
  • 起病定义可选用首次SSc表现或首次非雷诺表现,两者无实质差异。

临床怎么用

  • 设计早期弥漫性SSc临床试验时,建议将入组病程限制在<18个月以减少均值回归影响。
  • 起病定义可选择首次SSc表现或首次非雷诺表现,不影响入组标准效果。

局限性

  • 研究基于单中心前瞻性观察队列,结果外推需谨慎。
  • 原文未报告多中心验证或干预性试验的直接证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Clinical trials in early diffuse cutaneous systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome measure have most often been negative. We wanted to assess how the definition of disease onset (first SSc manifestation vs first non-Raynaud manifestation) and varying lengths of disease duration at trial entry as an inclusion criteria functioned. Our objective was to optimize trial inclusion criteria. METHODS: We used the prospective, observational University of Pittsburgh Scleroderma Cohort to identify early diffuse SSc patients first evaluated between 1980 and 2015. All had <3 years from first SSc (n = 481) or first non-Raynaud manifestation (n = 514) and three or more mRSS scores. We used descriptive, survival and group-based trajectory analyses to compare the different definitions of disease onset and disease duration as inclusion criteria for clinical trials. RESULTS: There was no appreciable difference between using first SSc manifestation compared with first non-Raynaud manifestation as the definition of disease onset. Compared with other disease durations, <18 months of disease had >70% of patients fitting into trajectories with worsening cutaneous disease over 6 months of follow-up. Longer disease durations demonstrated the majority of patients with trajectories showing an improvement in mRSS (regression to the mean) over 6 months. CONCLUSIONS: Regardless of whether the first SSc or first non-Raynaud manifestation is used to define disease onset, duration of <18 months at enrolment is preferable. A longer disease duration criterion more frequently results in regression to the mean of the mRSS score, and likely contributes to negative trial outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Domsic RT, Gao S, Laffoon M, et al. Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology (Oxford). 2021. PMID: 33506859. doi:10.1093/rheumatology/keab075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。